Albumin Market By Type, By Application, By Sales Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

Furthermore, the growth of the albumin market is propelled by the increasing implementation of key strategies among major industry players, including product launches, acquisitions, and agreements. For instance, in September 2020, Sartorius Group, a leading international partner of life science research and the biopharmaceutical industry, announced acquisition of Albumedix Ltd, a leader in the field of recombinant albumin-based solutions. In addition, Grifols, a leading global producer of plasma-derived medicines, announced the launch of its latest albumin portfolio innovation, ALBUTEIN FlexBag (Albumin [Human] U.S.P.) in 5% and 25% concentrations. These strategic moves not only drive innovation but also foster market growth by catering to the evolving needs of the healthcare and biopharmaceutical industries.

In addition, technological advancements are key drivers of the growing albumin market. In the pharmaceutical and biotechnology sectors, continuous innovations in production processes and purification techniques enhance the efficiency and quality of albumin products. Advanced technologies also contribute to the development of novel albumin-based formulations, expanding their applications in drug delivery systems and diagnostics. Precision in manufacturing, purification, and analysis ensures high-quality albumin with minimal impurities, meeting stringent regulatory standards. In addition, technological progress facilitates the exploration of alternative sources for albumin production, addressing supply chain challenges. The synergy between technology and albumin production not only improves existing products but also fosters the creation of cutting-edge solutions, fueling the overall expansion of the albumin market.

The albumin market is segmented on the basis of type, application, sales channel, and region. On the basis of type, the market is categorized into human serum albumin, bovine serum albumin, and recombinant albumin. On the basis of application, it is classified into therapeutics, drug formulation & vaccines, component of media, and others. On the basis of sales channel, it is classified into business to business (B2B) and business to consumer (B2C). On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major key players that operate in the global albumin market are Takeda Pharmaceutical Company Limited, Merck KGaA, Sartorius AG, Octapharma AG, Thermo Fisher Scientific Inc., Ventria Bioscience Inc, Grifols, S.A., CSL, China Biologic Products Holdings, Inc, and Lazuline Bio. The players have adopted investment, strategic alliance, product approval, clinical trials, expansion, agreement, and acquisition as the key strategies to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the albumin market analysis from 2022 to 2032 to identify the prevailing albumin market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the albumin market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global albumin market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Patient/epidemiology data at country, region, global level
Regulatory Guidelines
Additional company profiles with specific to client's interest
Expanded list for Company Profiles
Historic market data
Reimbursement Scenario
SWOT Analysis

Key Market Segments

By Type

Human Serum Albumin
Bovine Serum Albumin
Recombinant Albumin

By Application

Therapeutics
Drug Formulation and Vaccines
Component of Media
Other

By Sales Channel

B2C
B2B
- Type
- Pharmaceutical Applications

Type

Non Pharmaceutical Applications

Type

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Octapharma AG
Grifols, S.A.
CSL
Ventria Bioscience Inc.
Lazuline Bio
Takeda Pharmaceutical Company Limited
Sartorius AG
Merck KGaA
Thermo Fisher Scientific Inc.
China Biologic Products Holdings, Inc

Product Code: A02251

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in number of surgical procedures
  - 3.4.1.2. Growing awareness regarding blood donations.
  - 3.4.1.3. Rise in use of plasma derived albumin in drug development
- 3.4.2. Restraints
  - 3.4.2.1. Stringent government regulations
- 3.4.3. Opportunities
  - 3.4.3.1. Growth opportunities in emerging markets

CHAPTER 4: ALBUMIN MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Human Serum Albumin
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Bovine Serum Albumin
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Recombinant Albumin
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: ALBUMIN MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Therapeutics
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Drug Formulation and Vaccines
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Component of Media
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Other
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country

CHAPTER 6: ALBUMIN MARKET, BY SALES CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. B2C
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. B2B
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.3.4. B2B Albumin Market by Type
  - 6.3.4.1. Pharmaceutical Applications Albumin Market by Type
  - 6.3.4.2. Non Pharmaceutical Applications Albumin Market by Type

CHAPTER 7: ALBUMIN MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by Sales Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Market size and forecast, by Type
  - 7.2.5.1.2. Market size and forecast, by Application
  - 7.2.5.1.3. Market size and forecast, by Sales Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Market size and forecast, by Type
  - 7.2.5.2.2. Market size and forecast, by Application
  - 7.2.5.2.3. Market size and forecast, by Sales Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Market size and forecast, by Type
  - 7.2.5.3.2. Market size and forecast, by Application
  - 7.2.5.3.3. Market size and forecast, by Sales Channel
7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by Sales Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Market size and forecast, by Type
  - 7.3.5.1.2. Market size and forecast, by Application
  - 7.3.5.1.3. Market size and forecast, by Sales Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Market size and forecast, by Type
  - 7.3.5.2.2. Market size and forecast, by Application
  - 7.3.5.2.3. Market size and forecast, by Sales Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Market size and forecast, by Type
  - 7.3.5.3.2. Market size and forecast, by Application
  - 7.3.5.3.3. Market size and forecast, by Sales Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Market size and forecast, by Type
  - 7.3.5.4.2. Market size and forecast, by Application
  - 7.3.5.4.3. Market size and forecast, by Sales Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Market size and forecast, by Type
  - 7.3.5.5.2. Market size and forecast, by Application
  - 7.3.5.5.3. Market size and forecast, by Sales Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Market size and forecast, by Type
  - 7.3.5.6.2. Market size and forecast, by Application
  - 7.3.5.6.3. Market size and forecast, by Sales Channel
7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by Sales Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Market size and forecast, by Type
  - 7.4.5.1.2. Market size and forecast, by Application
  - 7.4.5.1.3. Market size and forecast, by Sales Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Market size and forecast, by Type
  - 7.4.5.2.2. Market size and forecast, by Application
  - 7.4.5.2.3. Market size and forecast, by Sales Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Market size and forecast, by Type
  - 7.4.5.3.2. Market size and forecast, by Application
  - 7.4.5.3.3. Market size and forecast, by Sales Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Market size and forecast, by Type
  - 7.4.5.4.2. Market size and forecast, by Application
  - 7.4.5.4.3. Market size and forecast, by Sales Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Type
  - 7.4.5.5.2. Market size and forecast, by Application
  - 7.4.5.5.3. Market size and forecast, by Sales Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Type
  - 7.4.5.6.2. Market size and forecast, by Application
  - 7.4.5.6.3. Market size and forecast, by Sales Channel
7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by Sales Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Market size and forecast, by Type
  - 7.5.5.1.2. Market size and forecast, by Application
  - 7.5.5.1.3. Market size and forecast, by Sales Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Market size and forecast, by Type
  - 7.5.5.2.2. Market size and forecast, by Application
  - 7.5.5.2.3. Market size and forecast, by Sales Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Market size and forecast, by Type
  - 7.5.5.3.2. Market size and forecast, by Application
  - 7.5.5.3.3. Market size and forecast, by Sales Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Market size and forecast, by Type
  - 7.5.5.4.2. Market size and forecast, by Application
  - 7.5.5.4.3. Market size and forecast, by Sales Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Merck KGaA
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Sartorius AG
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Octapharma AG
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Thermo Fisher Scientific Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Ventria Bioscience Inc.
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
9.6. Grifols, S.A.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. CSL
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. China Biologic Products Holdings, Inc
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
9.9. Lazuline Bio
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
9.10. Takeda Pharmaceutical Company Limited
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- 9.10.7. Key strategic moves and developments